

For Immediate Release

Net Profit up 144% to Rs 301 crores

Profit before Tax up 131% to Rs 368 crores

Vadodara July 22nd, 2020

Alembic Pharmaceuticals Limited reported its consolidated financial results for the quarter ending 30th June 2020.

Financial Highlights for Q1FY21

- Net Sales up 41% to Rs 1341 crores
- Profit before tax up 131% to Rs 368 crores
- Net Profit up 144% to Rs 301 crores

Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said

“It was an excellent quarter for the company backed by growth in all the international markets. Despite exceptionally challenging circumstances, the operating teams ensured profitability and growth.”

Operational Highlights

International Business

- International formulations grew 70% to Rs 771 crores in the quarter.
- US Generics grew 73% to Rs 596 crores in the quarter.
- Ex-US International Formulations grew 62% to Rs 175 crores in the quarter.
- 6 ANDA approvals received during the quarter, Cumulative ANDA approvals at 125 (including 14 tentative).
- 8 ANDA filings during the quarter; Cumulative ANDA filings at 191.

India Formulations Business

- India formulations business for the quarter de-grew by 6% to Rs 306 crores.



ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229
website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123

Summary of Total Revenue is as under:

(Rs in Crores)

Particulars	Q1 FY20	Q1 FY19	% Change
Formulation			
USA	596	345	73%
EX-USA	175	108	62%
India	306	324	-6%
API	264	172	54%
Total	1341	949	41%

The Profit break-up is as under:

(Rs in Crores)

Particulars	Q1 FY20	Q1 FY19	% Change
EBITDA	416	200	108%
EBITDA %	31%	21%	
Profit Before Tax after Exceptional Items	368	160	131%
Net Profit after Tax	301	124	144%


About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at www.alembicpharmaceuticals.com;
(reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

Ajay Kumar Desai Phone: +91 22 – 306 11681 Email: ajay.desai@alembic.co.in	Mitanshu Shah Phone: +91 265 – 3007630 Email: mitanshu.shah@alembic.co.in
---	---



ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229
website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123